Mullarkey Named CEO at Bluestar Genomics
11 January 2022 - - US-based early cancer detection company Bluestar Genomics, Inc has appointed David Mullarkey as chief executive officer, effective January 10, the company said.

Mullarkey will also join the company's board of directors.

Current acting chief executive officer and chief scientific officer Samuel Levy, Ph.D., to continue in his role as chief scientific officer.

Mullarkey brings an extensive track record of success across the life sciences industry of scaling and delivering value with therapeutic, diagnostic, and life science tools companies in both private and public settings.

Most recently, Mullarkey was president and chief executive officer of Omniome, where he raised over USD 150m and guided the DNA sequencing company from the early technology development through the delivery of a beta prototype leading to its sale to Pacific Biosciences in 2021.

Prior to Omniome, Mullarkey served as the president and chief operating officer of Ariosa Diagnostics, driving rapid global revenue growth and market development for the cell-free DNA non-invasive prenatal testing company resulting in the acquisition by Roche in 2014.

Post-acquisition, Mullarkey led the integration of the Ariosa business and served as a global lifecycle leader, site head for a 250-person CLIA Lab/R and D location, and a core member of the Roche Sequencing Solutions leadership team.

He has also held leadership positions at Johnson and Johnson, Eli Lilly and Company (NYSE: LLY), Valeant Pharmaceuticals and Dow Pharmaceutical Sciences.

Bluestar Genomics is an early cancer detection company focused on the development and commercialization of non-invasive epigenomic tests to detect cancer through a standard blood draw, earlier than existing methods and when the disease is still treatable.

The company uses its epigenomic platform that combines bioinformatics and genomic technologies to analyze individuals' changing biology that is yet to produce symptoms.

Leveraging its novel liquid biopsy technology, Bluestar Genomics is initially focused on high-mortality cancers with the greatest need for early detection, starting with pancreatic and women's cancers.

With locations in San Diego and the San Francisco Bay Area, Bluestar Genomics collaborates with top research institutions and is supported by multiple global healthcare and technology investors and pharmaceutical collaborations.